


## ATOPIC DERMATITIS TREATMENT PATHWAY (ADULTS)



The following is applicable to the High Cost Immunomodulator section only.

## Pathway definitions:

	Definition	Action
Primary Failure	Occurs when the response criteria (as defined within the NICE TA) is <b>not fully met</b> when response to treatment is assessed at the time interval defined within the NICE TA	Move to the NEXT treatment line/mode of action (if one is available)
Secondary Failure	Occurs when the response to treatment (as defined within the NICE TA) is <b>no longer met</b>	Move to the NEXT treatment line/mode of action (if one is available)
Primary intolerance/adverse effects	An occurrence that causes discontinuation of treatment, due to inability to tolerate side-effects of that treatment that occurs <b>during the initial time period defined by the NICE TA</b>	Use another option from the SAME treatment line
Secondary intolerance/adverse effects	An occurrence that causes discontinuation of treatment, due to inability to tolerate side effects of that treatment that occurs <b>after the initial time period defined by the NICE TA</b>	Move to the NEXT treatment line OR discuss at RN meeting
Conception	If conception plans or pregnancy indicate a change of drug is advisable, it is agreed that this <b>does not constitute a change in line of treatment</b>	Please update via Blueteq accordingly

## Drug choices and length of initial treatment before first review<sup>1</sup>:

Mode of action	Drug	Initial treatment length as specified by NICE TA	NICE TA
IL4 / 23 inhibitor	Dupilumab	16 weeks	TA534
JAK inhibitor (Oral)	Abrocitinib	16 weeks	TA814
	Baricitinib	16 weeks	TA681
	Upadacitinib	16 weeks	TA814
IL13 inhibitor	Tralokinumab	16 weeks	TA814

### Notes:

1. Embedded hyperlinks are either to NICE Clinical Knowledge Summaries, NICE Technical Appraisals [www.nice.org.uk](http://www.nice.org.uk), or pages within the Surrey [Prescribing Advisory Database \(res-systems.net\)](http://res-systems.net)

2. If patients on JAK inhibitors need to change therapy due to the MHRA alert<sup>2</sup> issued 26th April 2023, then this would be considered a change within the same treatment line.

### References:

- 1) NICE Technical Guidance TA81, TA82, TA534, TA681 & TA814. Available at <https://www.nice.org.uk>
- 2) Drug Safety Update. Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality. Available at: Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality

**Reviewed:** NHS Surrey Heartlands ICB Medicines Resource Unit  
**Agreed date:** Area Prescribing Committee October 2022

**Input from:** Dermatology Network - September 2022  
**Review date:** October 2025